The inhalation therapy had been
practiced by ancient civilizations in Egypt, India, Greece, and China.
Proven records of use of the therapy for thousands of years are
available. In order to resolve respiratory issues, the pulmonary method
of administration has been effective in terms of confined and systemic
supply of several drugs and biopharmaceuticals. The only reason for the
lack of desired outcome or an unfavorable effect is inappropriate
utilization of devices and improper training for handling of devices. At
present, inhalation therapy is considered the best solution for lung
diseases such as chronic obstructive pulmonary disease (COPD), asthma,
and cystic fibrosis. The therapy permits the use of smaller doses and
reduces systemic side-effects. Chronic obstructive pulmonary disease
(COPD) is ranked by the World Health Organization (WHO) as one of the
most prevalent long-term conditions in the world. The global burden of
COPD is projected to rise in the near future, particularly in developing
countries, due to increasing elderly population, growing habit of
smoking, and rising pollution. Rising incidence of pulmonary diseases
across the globe is a major factor fueling the global inhalation systems
market.
The global inhalation systems market is
primarily driven by rising prevalence of COPD, asthma, and chronic
respiratory diseases; growing geriatric population facing chronic
respiratory problems; and changing lifestyle. Moreover, introduction of
novel and advanced pulmonary devices in customized shapes and sizes,
availability of auto-injectors, and rise in research and developmental
activities by pharmaceutical and biotechnology companies in order to
develop novel oral and nasal drug formulations are some of the other
important factors likely to drive the market from 2017 to 2025. However,
complications and side-effects associated with drug inhalation,
unavailability of a single effective inhaler device that can treat
multiple disease indications, and lack of awareness are other factors
restraining the market. Health care at home, campaigning by
manufacturers and hospitals to increase awareness about respiratory
diseases, and technological advancements are the current trends in the
market for inhalation systems.
The global inhalation systems market has
been segmented based on product, disease indication, end-user, and
geography. Based on product, the market has been segmented into
inhalers, nebulizers, nasal sprays, and others. The inhalers segment has
been sub-divided into dry powder inhalers (DPIs), metered dose inhalers
(MDIs), and multi-dose liquid inhalers. The nebulizers segment has been
sub-segmented into ultrasonic nebulizers, compressed air-jet
nebulizers, mesh nebulizers, and others. In terms of revenue, the
inhalers segment is anticipated to hold a major share of the global
inhalation systems market by 2025. It is expected to dominate the market
from 2017 to 2025.
In terms of disease indication, the
global inhalation systems market has been divided into asthma, chronic
obstructive pulmonary disease (COPD), cystic fibrosis, anesthesia, nasal
congestion, and others. According to a study conducted by the World
Health Organization (WHO), chronic obstructive pulmonary disease was
found to be the fifth cause of deaths globally in 2002 and is projected
to be the fourth cause of mortality by 2030. Moreover, according to the
WHO estimates, 65 million people have moderate to severe COPD. More than
3 million people died of COPD in 2005, which equaled to 5% of all
deaths worldwide. Rising awareness about COPD and technological
advancements in product offerings are major factors expected to fuel the
COPD segment during the forecast period.
Based on end-user, the global inhalation
systems market has been segmented into hospitals & clinics,
ambulatory surgery centers, home care centers, and others. Among these,
the home care centers segment is expected to register the maximum growth
rate during the forecast period, owing to rising geriatric population,
increasing per capita expenditure, and growing awareness about
respiratory diseases. A survey conducted by the Healthcare First
organization concludes that more than 3.4 million people in the U.S.
receive Medicare skilled home health care services, due to rising
elderly population and increasing incidence of chronic health conditions
in the country. Geographically, the global inhalation systems market
has been classified into North America, Europe, Asia Pacific, Latin
America, and Middle East & Africa. North America is anticipated to
dominate the global market in the near future. The market in the region
is likely to witness significant growth during the forecast period,
owing to affordability of advanced products and rising prevalence of
lifestyle-related diseases.
Key players operating in the global
inhalation systems market are 3M, Boehringer Ingelheim GmbH, AptarGroup,
Inc., Koninklijke Philips N.V., PARI GmbH, Trudell Medical
International, Teleflex Incorporated, INSPIRO Medical Ltd., ALEXZA, and
Monaghan Medical Corporation.
No comments:
Post a Comment